000 | 01130 a2200325 4500 | ||
---|---|---|---|
005 | 20250517053626.0 | ||
264 | 0 | _c20151209 | |
008 | 201512s 0 0 eng d | ||
022 | _a1539-2864 | ||
024 | 7 |
_a10.1097/IAE.0000000000000725 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBrown, David M | |
245 | 0 | 0 |
_aReply: To PMID 24914476. _h[electronic resource] |
260 |
_bRetina (Philadelphia, Pa.) _cOct 2015 |
||
300 |
_ae61-3 p. _bdigital |
||
500 | _aPublication Type: Letter; Comment | ||
650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIschemia _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aRetinal Vein Occlusion _xdrug therapy |
650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
700 | 1 | _aWykoff, Charles C | |
700 | 1 | _aCroft, Daniel E | |
700 | 1 | _aWong, Tien P | |
773 | 0 |
_tRetina (Philadelphia, Pa.) _gvol. 35 _gno. 10 _gp. e61-3 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/IAE.0000000000000725 _zAvailable from publisher's website |
999 |
_c25288097 _d25288097 |